Biologics for bowel disease face threat from cheaper small molecules
Drug Discovery World
DECEMBER 21, 2023
The increase in IBD biologic treatments has been a major driving force in the growth of this market in recent years. Biologics need to justify cost Companies in this sector will need to contend with the emergence of novel small molecules, particularly Janus kinase (JAK) and sphingosine 1 phosphate receptor modulators (S1PR).
Let's personalize your content